Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial
Abstract High-sensitivity C-reactive protein (hs-CRP) is independently associated with cardiovascular events in coronary artery disease (CAD) patients and reducing the hs-CRP level may further benefit this population. We conduct this parallel design, randomized-controlled trial to assess the effecti...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/19d228d5a810411685889f9f1fc287e3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:19d228d5a810411685889f9f1fc287e3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:19d228d5a810411685889f9f1fc287e32021-12-02T15:06:12ZSodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial10.1038/s41598-017-16980-42045-2322https://doaj.org/article/19d228d5a810411685889f9f1fc287e32017-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-16980-4https://doaj.org/toc/2045-2322Abstract High-sensitivity C-reactive protein (hs-CRP) is independently associated with cardiovascular events in coronary artery disease (CAD) patients and reducing the hs-CRP level may further benefit this population. We conduct this parallel design, randomized-controlled trial to assess the effectiveness of adjunct sodium tanshinone IIA sulfate (STS) therapy on circulating inflammation markers in CAD patients. Unstable angina or non-ST-elevation myocardial infarction patients with increased hs-CRP level were randomly assigned to atorvastatin-based standard medical therapy or standard therapy plus STS injection (80 mg, once daily for 14 consecutive days). The primary outcome was hs-CRP level. After the 14-day treatment, the experimental group (n = 35) exhibited significantly lower levels of hs-CRP than the control group (n = 35) (1.72 vs 3.20 mg/L, p = 0.0191). Lower levels of interleukin-6, monocyte chemotactic protein-1 (MCP-1), and soluble CD40 ligand were also observed in the experimental group. Angina symptoms were also better controlled in the experimental group. At 30 days after treatment completion, MCP-1 levels remained lower in the experimental group than in the control group (313.88 vs 337.91 pg/mL, p = 0.0078). No serious adverse events occurred. Our study demonstrates that on the basis of standard medical therapy, STS further reduce elevated hs-CRP and other circulating inflammation markers in CAD patients. (Chictr.org number: ChiCTR-TRC-12002361).Siming LiYang JiaoHanjay WangQinghua ShangFang LuLi HuangJiangang LiuHao XuKeji ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Siming Li Yang Jiao Hanjay Wang Qinghua Shang Fang Lu Li Huang Jiangang Liu Hao Xu Keji Chen Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial |
| description |
Abstract High-sensitivity C-reactive protein (hs-CRP) is independently associated with cardiovascular events in coronary artery disease (CAD) patients and reducing the hs-CRP level may further benefit this population. We conduct this parallel design, randomized-controlled trial to assess the effectiveness of adjunct sodium tanshinone IIA sulfate (STS) therapy on circulating inflammation markers in CAD patients. Unstable angina or non-ST-elevation myocardial infarction patients with increased hs-CRP level were randomly assigned to atorvastatin-based standard medical therapy or standard therapy plus STS injection (80 mg, once daily for 14 consecutive days). The primary outcome was hs-CRP level. After the 14-day treatment, the experimental group (n = 35) exhibited significantly lower levels of hs-CRP than the control group (n = 35) (1.72 vs 3.20 mg/L, p = 0.0191). Lower levels of interleukin-6, monocyte chemotactic protein-1 (MCP-1), and soluble CD40 ligand were also observed in the experimental group. Angina symptoms were also better controlled in the experimental group. At 30 days after treatment completion, MCP-1 levels remained lower in the experimental group than in the control group (313.88 vs 337.91 pg/mL, p = 0.0078). No serious adverse events occurred. Our study demonstrates that on the basis of standard medical therapy, STS further reduce elevated hs-CRP and other circulating inflammation markers in CAD patients. (Chictr.org number: ChiCTR-TRC-12002361). |
| format |
article |
| author |
Siming Li Yang Jiao Hanjay Wang Qinghua Shang Fang Lu Li Huang Jiangang Liu Hao Xu Keji Chen |
| author_facet |
Siming Li Yang Jiao Hanjay Wang Qinghua Shang Fang Lu Li Huang Jiangang Liu Hao Xu Keji Chen |
| author_sort |
Siming Li |
| title |
Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial |
| title_short |
Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial |
| title_full |
Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial |
| title_fullStr |
Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial |
| title_full_unstemmed |
Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial |
| title_sort |
sodium tanshinone iia sulfate adjunct therapy reduces high-sensitivity c-reactive protein level in coronary artery disease patients: a randomized controlled trial |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/19d228d5a810411685889f9f1fc287e3 |
| work_keys_str_mv |
AT simingli sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial AT yangjiao sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial AT hanjaywang sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial AT qinghuashang sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial AT fanglu sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial AT lihuang sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial AT jiangangliu sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial AT haoxu sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial AT kejichen sodiumtanshinoneiiasulfateadjuncttherapyreduceshighsensitivitycreactiveproteinlevelincoronaryarterydiseasepatientsarandomizedcontrolledtrial |
| _version_ |
1718388563950698496 |